These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34638407)

  • 21. Molecular Classification of Colorectal Cancer by microRNA Profiling: Correlation with the Consensus Molecular Subtypes (CMS) and Validation of miR-30b Targets.
    Paz-Cabezas M; Calvo-López T; Romera-Lopez A; Tabas-Madrid D; Ogando J; Fernández-Aceñero MJ; Sastre J; Pascual-Montano A; Mañes S; Díaz-Rubio E; Perez-Villamil B
    Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Microenvironment, systemic inflammatory response and tumor markers considering consensus molecular subtypes of colorectal cancer.
    Jakab A; Patai ÁV; Darvas M; Tormássi-Bély K; Micsik T
    Pathol Oncol Res; 2024; 30():1611574. PubMed ID: 38645565
    [No Abstract]   [Full Text] [Related]  

  • 23. Seed and Soil: Consensus Molecular Subgroups (CMS) and Tumor Microenvironment Features Between Primary Lesions and Metastases of Different Organ Sites in Colorectal Cancer.
    Luo Q; Quan Y; Liu W; Wu Z; Qiu W; Liang W; Yang P; Huang Q; Li G; Wei J; Wang Q; Shen F; Li W; He F; Cao J
    Cancer Manag Res; 2024; 16():225-243. PubMed ID: 38525373
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of mitochondrial complex I induces ROS production in colorectal cancer subtypes that differently controls migration.
    Bastin J; Sroussi M; Nemazanyy I; Laurent-Puig P; Mouillet-Richard S; Djouadi F
    J Transl Med; 2023 Aug; 21(1):522. PubMed ID: 37533102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.
    Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E
    Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.
    Chang K; Willis JA; Reumers J; Taggart MW; San Lucas FA; Thirumurthi S; Kanth P; Delker DA; Hagedorn CH; Lynch PM; Ellis LM; Hawk ET; Scheet PA; Kopetz S; Arts J; Guinney J; Dienstmann R; Vilar E
    Ann Oncol; 2018 Oct; 29(10):2061-2067. PubMed ID: 30412224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multi-omics integration identifies a selective vulnerability of colorectal cancer subtypes to YM155.
    Zhan T; Faehling V; Rauscher B; Betge J; Ebert MP; Boutros M
    Int J Cancer; 2021 Apr; 148(8):1948-1963. PubMed ID: 33186476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
    Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
    Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSRP1 expression is associated with a mesenchymal, stroma-rich tumor profile and poor prognosis in colon cancer.
    Demirkol Canli S
    Turk J Med Sci; 2023; 53(6):1678-1689. PubMed ID: 38813484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a miRNA-based classifier for detection of colorectal cancer molecular subtypes.
    Adam RS; Poel D; Ferreira Moreno L; Spronck JMA; de Back TR; Torang A; Gomez Barila PM; Ten Hoorn S; Markowetz F; Wang X; Verheul HMW; Buffart TE; Vermeulen L
    Mol Oncol; 2022 Jul; 16(14):2693-2709. PubMed ID: 35298091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer.
    Joanito I; Wirapati P; Zhao N; Nawaz Z; Yeo G; Lee F; Eng CLP; Macalinao DC; Kahraman M; Srinivasan H; Lakshmanan V; Verbandt S; Tsantoulis P; Gunn N; Venkatesh PN; Poh ZW; Nahar R; Oh HLJ; Loo JM; Chia S; Cheow LF; Cheruba E; Wong MT; Kua L; Chua C; Nguyen A; Golovan J; Gan A; Lim WJ; Guo YA; Yap CK; Tay B; Hong Y; Chong DQ; Chok AY; Park WY; Han S; Chang MH; Seow-En I; Fu C; Mathew R; Toh EL; Hong LZ; Skanderup AJ; DasGupta R; Ong CJ; Lim KH; Tan EKW; Koo SL; Leow WQ; Tejpar S; Prabhakar S; Tan IB
    Nat Genet; 2022 Jul; 54(7):963-975. PubMed ID: 35773407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy.
    Yang M; Davis TB; Pflieger L; Nebozhyn MV; Loboda A; Wang H; Schell MJ; Thota R; Pledger WJ; Yeatman TJ
    BMC Cancer; 2022 Mar; 22(1):256. PubMed ID: 35272617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phenotypic subtypes predict outcomes in colorectal cancer.
    Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
    Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective patient stratification into robust cancer-cell intrinsic subtypes from colorectal cancer biopsies.
    Alderdice M; Richman SD; Gollins S; Stewart JP; Hurt C; Adams R; McCorry AM; Roddy AC; Vimalachandran D; Isella C; Medico E; Maughan T; McArt DG; Lawler M; Dunne PD
    J Pathol; 2018 May; 245(1):19-28. PubMed ID: 29412457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Ten Hoorn S; de Back TR; Sommeijer DW; Vermeulen L
    J Natl Cancer Inst; 2022 Apr; 114(4):503-516. PubMed ID: 34077519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential CMS-Related Expression of Cell Surface Carbonic Anhydrases IX and XII in Colorectal Cancer Models-Implications for Therapy.
    Rotermund A; Brandt S; Staege MS; Luetzkendorf J; Mueller LP; Mueller T
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consensus molecular subtypes (CMS) in metastatic colorectal cancer - personalized medicine decision.
    Rebersek M
    Radiol Oncol; 2020 May; 54(3):272-277. PubMed ID: 32463385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RNA-Seq-Based Molecular Classification Analyses in Colorectal Cancer and Synchronous Adenoma.
    Choi JW; Lee GY; Kim S; Ahn K; Do IG; Jung KU; Kim HO; Kim H; Park DI; Park SK
    Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approach.
    Valenzuela G; Canepa J; Simonetti C; Solo de Zaldívar L; Marcelain K; González-Montero J
    World J Clin Oncol; 2021 Nov; 12(11):1000-1008. PubMed ID: 34909395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.